e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Biomarkers and exacerbations of asthma and COPD
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma
M. Hübner, S. Korn, M. Jung, I. Haasler, C. Taube, R. Buhl (Mainz, Germany)
Source:
Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD
Session:
Biomarkers and exacerbations of asthma and COPD
Session type:
Poster Discussion
Number:
3352
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Hübner, S. Korn, M. Jung, I. Haasler, C. Taube, R. Buhl (Mainz, Germany). Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma. Eur Respir J 2011; 38: Suppl. 55, 3352
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Allergic inflammation markers for earlier diagnosis of bronchial asthma in patients with allergic rhinitis
Source: Annual Congress 2008 - Asthma: growing understanding of influential factors
Year: 2008
Heterogeneous response of airway eosinophilia to biologics in severe asthma patients
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021
IL-33 in patients with severe uncontrolled allergic asthma
Source: International Congress 2017 – "Alarming" immunological patterns in asthma
Year: 2017
Clinical and histological impact of omalizumab in oral corticosteroid-dependent severe allergic asthma
Source: International Congress 2019 – Novel findings from asthma clinical trials
Year: 2019
Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009
Clinical response to mepolizumab in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Markers of eosinophilic inflammation are associated with response to the DP2 antagonist GB001 in patients with mild atopic asthma
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019
Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009
Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Airway inflammation in non-eosinophilic atopic asthma: comparisons with eosinophilic atopic asthma and COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 733s
Year: 2005
Clinical outcome of eosinophilic airway inflammation in chronic airway diseases including nonasthmatic eosinophilic bronchitis
Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside
Year: 2017
Efficacy of montelukast in patients with concomitan persistent allergic rhinitis and asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 663s
Year: 2006
Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
Factors driving airway eosinophilia in prednisone-dependent severe asthma
Source: International Congress 2017 – Pathophysiology and emerging therapies for severe asthma
Year: 2017
Airway autoimmunity and response to a 14-day course of oral corticosteroids in patients with severe eosinophilic asthma
Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma
Year: 2020
Markers of severity and inflammatory profile during exacerbations of severe asthma.
Source: International Congress 2017 – Airway disease and exacerbations
Year: 2017
Inflammatory profile of patients with allergic asthma & rhinitis
versus
patients with allergic rhinitis alone
Source: Annual Congress 2007 - Mechanisms of inflammation in asthma and rhinitis - from cell cultures to patients
Year: 2007
Mepolizumab in real-life treatment of severe eosinophilic asthma
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Effects of formoterol-budesonide combination on residual eosinophilic inflammation in distal airway of patients with well-controlled moderate asthma
Source: Annual Congress 2011 - Asthma management and response
Year: 2011
Real-life treatment of severe eosinophilic asthma with mepolizumab
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept